Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PRESCIENT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05556746 |
|
Recruitment Status :
Recruiting
First Posted : September 27, 2022
Last Update Posted : January 29, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that will compare a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible pulmonary tuberculosis. Eligible participants will be randomized in a 1:1 ratio to BDQ, CFZ, PZA, and DLM (BCZD) or standard anti-TB therapy.
Participants in the experimental arm with evidence of poor clinical response at the end of therapy will be re-treated with standard TB therapy. The primary analysis is a superiority efficacy comparison of time to liquid culture conversion through 8 weeks in the experimental (BCZD) arm vs. the standard therapy arm. The other key secondary outcome is safety.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tuberculosis, Pulmonary HIV | Drug: Bedaquiline Drug: Clofazimine Drug: Pyrazinamide Drug: Delamanid Drug: Rifampin Drug: Isoniazid Drug: Ethambutol | Phase 2 |
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that will compare a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible pulmonary tuberculosis. Eligible participants will be randomized in a 1:1 ratio to BDQ, CFZ, PZA, and DLM (BCZD) or standard anti-TB therapy. Randomization will be stratified by presence of lung cavitation and HIV status.
Participants will be randomized to one of two arms:
Arm 1 (Experimental): BDQ 200 mg for 12 weeks + PZA 1000 - 2000 mg (according to weight) for 12 weeks + CFZ 300 mg for 2 weeks, followed by 100 mg for 10 weeks + DLM 200 mg for 12 weeks, all given once daily.
Arm 2 (Standard of Care): RIF, INH, EMB and PZA for 8 weeks, followed by RIF and INH for 18 weeks.
Medications will be given daily in fixed dose combinations at standard weight-based doses. Adherence will be supported through automated reminders and monitored remotely in real time with Wisepill electronic adherence monitoring devices or with directly observed treatment. Participants in the experimental arm with evidence of poor clinical response will be re-treated with standard TB therapy. The primary analysis is a superiority efficacy comparison of time to liquid culture conversion through 8 weeks in the experimental (BCZD) arm vs. the standard therapy arm. Participants will have extended post-treatment follow up to evaluate clinical efficacy as a secondary composite outcome measure at 86 weeks after randomization (74 weeks after completion of experimental therapy, when most relapses are expected to occur). The other key secondary outcome is safety, measured as the proportion with new Grade 3 or higher adverse events; we shall focus on QTcF prolongation and hepatitis as adverse events of special interest. Through an efficient Phase IIc design, the PRESCIENT trial will test microbiological efficacy, evaluate safety, and detect treatment-emergent resistance with the ultra-short BCZD regimen. PRESCIENT will provide rapid evidence for microbiological efficacy as well as key information on safety and clinical treatment outcomes to inform the feasibility and promise of a subsequent phase III treatment-shortening trial.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 156 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Participants will be randomized in a 1:1 ratio to the experimental or standard groups. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT) |
| Actual Study Start Date : | November 24, 2023 |
| Estimated Primary Completion Date : | June 2025 |
| Estimated Study Completion Date : | January 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: BCZD
Bedaquiline 200 mg for 12 weeks + pyrazinamide 1000 - 2000 mg (according to weight) for 12 weeks + clofazimine 300 mg for 2 weeks, followed by 100 mg for 10 weeks + delamanid 200 mg for 12 weeks, all given once daily.
|
Drug: Bedaquiline
Daily therapy for 12 weeks Drug: Clofazimine Daily therapy for 12 weeks Drug: Pyrazinamide Daily therapy for 12 weeks Drug: Delamanid Daily therapy for 12 weeks |
|
Active Comparator: Standard TB Treatment
Rifampin, isoniazid, ethambutol and pyrazinamide for 8 weeks, followed by rifampin and isoniazid for 18 weeks; given daily in fixed dose combinations at standard weight-based doses.
|
Drug: Rifampin
Daily therapy for 26 weeks Drug: Isoniazid Daily therapy for 26 weeks Drug: Ethambutol Daily therapy for 8 weeks Drug: Pyrazinamide Daily therapy for 8 weeks |
- Time to stable liquid culture conversion [ Time Frame: Measured through Week 8 ]Defined as the first of two negative sputum cultures, consecutive or not, without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs or symptoms of active TB
- Proportion experiencing any Grade 3 or higher AE [ Time Frame: Measured at Week 60 ]
AE includes any occurrence that is new in onset or aggravated at least one-grade from baseline.
AE's will be graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, July 2017.
- Proportion with favorable composite outcome [ Time Frame: Measured at Week 60 ]Defined as no failure, relapse, or non-accidental death
- Proportion who prematurely discontinue treatment [ Time Frame: Measured at Week 12 in experimental group and Week 26 in standard group ]Defined as discontinuation other than due to violent death, natural disaster, or administrative censoring
- Change in skin coloration [ Time Frame: Measured through Week 60 ]Mean change in subjective 10-point numeric rating scale where 0=none, 10=worst possible change in coloration
- Distress related to skin coloration [ Time Frame: Measured through Week 60 ]Mean subjective distress related to skin coloration on 10-point rating scale where 0=non, 10-worst possible distress due to coloration
- Mean change in QTcF from baseline to week 2, 8, 12, 16 and 20 [ Time Frame: Measured through Week 20 ]The QTcF is derived from ECG readings, which the sites conduct in triplicate (three ECGs 5-10 minutes apart). The mean of all measurements (up to 3) that are readable and available will be used at each of baseline (screening visit), Week 2, Week 8, Week 12, Week 16 and Week 20.
- Mean change in QTcF from baseline to end of treatment [ Time Frame: Measured at Week 12 in Arm 1 and Week 26 in Arm 2 ]The QTcF is derived from ECG readings, which the sites conduct in triplicate (three ECGs 5-10 minutes apart). The mean of all measurements (up to 3) that are readable and available will be used at baseline (screening visit), week 12 (Arm 1) and week 26 (Arm 2).
- Occurrence of absolute QTcF ≥480 ms and <500 ms, and ≥500 ms [ Time Frame: Measured through Week 20 in Arm 1 and through Week 26 in Arm 2 ]The QTcF is derived from ECG readings, which the sites conduct in triplicate (three ECGs 5-10 minutes apart). The mean of all measurements (up to 3) that are readable and available will be used at week 20 (Arm 1) and week 26 (Arm 2).
- Occurrence of QTcF change from baseline of ≥30 ms and <60 ms, and ≥60 ms [ Time Frame: Measured through Week 16 in experimental group and Week 26 in standard group ]The QTcF is derived from ECG readings, which the sites conduct in triplicate (three ECGs 5-10 minutes apart). The mean of all measurements (up to 3) that are readable and available will be used at week 20 (Arm 1) and week 26 (Arm 2).
- Proportion of participants with one or more serious adverse events (SAEs) [ Time Frame: Week 60 ]Serious adverse events reported at any time during participation in the trial
- Proportion with culture conversion in liquid and solid media (separately) at weeks 4, 8 and 12 after randomization [ Time Frame: Measured at Weeks 4, 8, and 12 ]Proportion of participants who have achieved stable culture conversion, defined as two negative sputum cultures, consecutive or not, without an intervening positive culture and/or visits wherein the participant is unable to produce sputum and has no signs of active TB; occurring before or at the week 4 or 8 visit, respectively
- Proportion with TB relapse (by M. tuberculosis genotyping) from end of treatment to 60 weeks [ Time Frame: Measured through Week 60 ]For participants who had successful culture conversion through the end of study treatment, TB relapse is defined as a recurrence of TB emanating from the same strain as the participant's originally diagnosed TB, which will be determined through whole genome sequencing.
- Proportion of treatment-emergent genotypic and phenotypic resistance to BCZD [ Time Frame: Measured through Week 60 ]For participants in experimental group only. MIC values will be evaluated against resistance-associated variants for paired baseline and failure isolates. Frequencies and proportions with phenotypic and/or genotypic resistance to any drug will be reported
- Time (days) to positivity in liquid culture (MGIT) after start of treatment across study arms [ Time Frame: Measured through Week 8 ]Median (Q1, Q3) times to positivity in liquid culture at each time point (Weeks 1, 2, 3, 4, 6, and 8) in Arm 1 and Arm 2.
- Time to stable liquid culture conversion [ Time Frame: Measured through Week 12 ]Defined as the first of two negative sputum cultures, consecutive or not, without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs or symptoms of active TB
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Informed consent obtained and signed.
- Male or female, aged ≥18 years.
- Pulmonary TB diagnosed by Xpert MTB/RIF, Xpert MTB/RIF Ultra, Line Probe Assay (LPA), or mycobacterial culture.
- Sputum positive for acid fast bacilli (at least 1+ grade on the WHO scale).
- Pulmonary TB diagnosed without known INH resistance (by LPA or Xpert MTB/XDR) and without known RIF resistance (by either LPA or Xpert). Note that phenotypic DST for INH resistance will be done on screening cultures (using MGIT). If baseline molecular or phenotypic test results that become available after enrollment detect resistance to INH or RIF, the participant will be a late exclusion from the study.
- Newly diagnosed with TB and have a history of being untreated for at least 6 months after cure from a previous episode of TB.
- For participants living with HIV, CD4+ cell count ≥200 cells/mm3, obtained within 30 days prior to study entry. Enrollment of participants living with HIV will be limited to no more than 20% of the total study population.
- For participants living with HIV, must be currently receiving or planning to initiate ART at or before study week 8.
-
Laboratory values at study screening:
- Alanine aminotransferase (ALT) ≤3x the upper limit of normal (ULN)
- Total bilirubin ≤2.5 x ULN
- Creatinine ≤2 x ULN
- Potassium ≥3.5 mEq/L, ≤5.5 mEq/L
- Absolute neutrophil count (ANC) ≥650/mm3
- Hemoglobin ≥7.0g/dL
- Platelet count ≥50,000/mm3
- For females of reproductive potential, negative serum or urine pregnancy test within 3 days prior to entry and willingness to use effective contraception for the duration of the study. Female participants who are not of reproductive potential must have documentation of menopause, hysterectomy, or bilateral oophorectomy or bilateral tubal ligation. Acceptable forms of contraception include: condoms, intrauterine device or intrauterine system, cervical cap with spermicide, diaphragm with spermicide.
- The initial 25% of enrollment will be restricted to participants (n = 39) with mild or moderate disease, defined as having sputum with higher Xpert MTB/RIF cycle threshold (Ct) values (> 18 cycles) and the absence of extensive lung disease on chest X-ray (involvement of at least half of the area of the entire thoracic cavity). Thereafter, all eligible patients will be offered participation without a pause in enrollment.
Exclusion Criteria:
- More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
- Current extrapulmonary TB (e.g. neurological, skeletal, abdominal, or nodal), not including pleural TB, in the opinion of the site investigator.
- Pregnant or breastfeeding.
- Weight <30kg.
- Inability to take oral medications.
- Current or planned use of any drug known to severely prolong the QTc interval, including, but not limited to: amiodarone, amitriptyline, chloroquine, chlorpromazine, cisapride, disopyramide, erthyromycin, moxifloxacin, procainamide, quinidine, or sotalol.
- Current or planned use of one or more of the following HIV medications: HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, elvitegravir/cobicistat, or bictegravir.
- Current or past use of clofazimine, bedaquiline or delamanid.
- QTcF >450ms for men or >470 ms for women.
- Current or history of known personal or family long QT syndrome.
- Known allergy/sensitivity to components of study TB drugs or their formulation.
Microbiologic confirmation of drug-susceptible TB is not always available at the time of enrollment. Enrolled individuals who are subsequently determined to meet either of the following criteria will be classified as late exclusions and study treatment will be discontinued. These participants will be transitioned to routine care but requested to remain in study follow up for safety evaluations.
A. Screening, baseline study, and Week 1 visit sputum cultures fail to grow M. tuberculosis.
B. Resistance to RIF or INH is detected from baseline molecular or phenotypic testing results that become available after enrollment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05556746
| Contact: Serena Koenig, MD | 617-413-4090 | skoenig@bwh.harvard.edu |
| Haiti | |
| GHESKIO | Recruiting |
| Port-au-Prince, Haiti | |
| Contact: Patrice Severe, MD 50934485963 patsevere@gheskio.org | |
| Principal Investigator: Patrice Severe, MD | |
| South Africa | |
| University of Cape Town | Recruiting |
| Cape Town, South Africa | |
| Contact: Attie Stadler, MBChB, MPH 27767050501 attiestadler@gmail.com | |
| Principal Investigator: Attie Stadler, MBChB, MPH | |
| Principal Investigator: | Serena Koenig, MD, MPH | Brigham and Women's Hospital | |
| Principal Investigator: | Sean Wasserman, MBChB, PhD | University of Cape Town |
| Responsible Party: | Serena Patricia Koenig, Associate Professor, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT05556746 |
| Other Study ID Numbers: |
2022p003075 U01AI170426 ( U.S. NIH Grant/Contract ) |
| First Posted: | September 27, 2022 Key Record Dates |
| Last Update Posted: | January 29, 2024 |
| Last Verified: | January 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Where possible, we will make raw data available in publications (directly or through online appendices). Although the final dataset will be stripped of identifiers prior to release for sharing, we believe there remains the possibility of deductive disclosure of subjects with unusual characteristics. We will therefore make the data and associated documentation available to users under a controlled access process/data-sharing agreement, in compliance with current international standards to protect participant confidentiality. Where applicable, data documentation and de-identified data will be deposited for sharing along with demographics consistent with applicable laws and regulations. Data content, format, and organization will conform with relevant data and terminology standards. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Pulmonary Tuberculosis Treatment Shortening HIV Drug-Susceptible Tuberculosis |
|
Tuberculosis Tuberculosis, Pulmonary Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections Respiratory Tract Infections Lung Diseases Respiratory Tract Diseases Rifampin Clofazimine Isoniazid Pyrazinamide |
Ethambutol Bedaquiline Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Leprostatic Agents Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP2C8 Inducers Cytochrome P-450 CYP2C19 Inducers Cytochrome P-450 CYP2C9 Inducers |